According to the World Health Organization (WHO), breast, lung, colorectal, cervical and stomach cancers these are five types of cancer that kill women more frequently comparatively other types of cancer in 2018. Increasing the prevalence of cancer in women is driving the growth of the cancer biomarker market.
According to the American Cancer Society, tobacco use is the single largest preventable cause of cancer across the globe. Approximately 30-50% of population of cancer suffered from smoking habit. Thus, increasing prevalence of smoking is driving the growth of the cancer biomarker market on account of increasing prevalence of cancer.
The global cancer biomarker market is segmented by type, cancer type, profiling technology, and application.
On the basis the type, the market is segmented into protein biomarker, genetic biomarker, and other.
Based on the cancer type, the cancer biomarker market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, non-hodgkin’s lymphoma, melanoma, leukemia, thyroid cancer, bladder cancer, kidney cancer, and other cancers. Breast cancer is expected to hold the major share during forecast period.
On the basis of profiling technology the cancer biomarker market is segmented into genomics, proteomics, omics technologies, imaging technologies, other omics technology, ultrasound, CT, MRI, PET, mammography, immunoassays, cytogenetics, in situ hybridization, and other cytogenetics, bioinformatics.
Based on the application the cancer biomarker market is segmented into diagnostics, research, prognostics, risk assessment, and other applications. Prognostics segments is expected to hold major market share of cancer biomarker market.
The global cancer biomarker market is divided into four major regions such as North America, Europe, Asia Pacific (APAC), and Latin America and Middle East & Africa (LAMEA).
North America is likely to hold the largest share in the global cancer biomarker market during forecast period. According to the American Society of Cancer during (2006-2015), approximately 1,762,450 new cancer cases of cancer diagnosed and around 606,880 deaths from cancer are expected to occur in the U.S. in 2019.
Europe is projected to be the second leading region in the global cancer biomarker market. According to the Cancer Research Centre of U.K., in 2015, approximately 38% of population suffered by cancer in U.K. Rise in number of cases of cancer is driving the growth of the cancer biomarker market. Increasing prevalence of obesity is influence chronic diseases such as cancer and diabetes is supporting the growth of the cancer biomarker market.
Asia Pacific (APAC) is expected to be the fastest growing region during the forecast period 2019–2026. Increasing geriatric population and E-smoker population is major influence for the cancer biomarker market. Furthermore, increasing prevalence of cervical cancer in India and China is propelling the growth of the market.
LAMEA is expecting a steady growth owing to undeveloped healthcare infrastructure. Additionally, lack of awareness about the healthy lifestyle is slowing the cancer biomarker market in this region.
The cancer biomarkers market is dominated by some players include Thermo Fisher Scientific, Qiagen N.V., Roche Diagnostics, Illumina, Hologic, Abbott Laboratories, Merck & Co., Becton Dickinson and Company, and Agilent Technologies.
By Cancer Type
By Profiling Technology